115 Years of Collective Experience
in the US Specialty Pharma Industry
Chairman Chief Executive Officer
Seamus Mulligan. founder of Adapt Pharma, serves as Chairman and Chief Executive Officer. Previously, Seamus was founder, Chairman, and Chief Executive Officer of Azur Pharma, which merged with Jazz Pharmaceuticals plc in 2012. Seamus continues to serve on the Board of Directors at Jazz Pharmaceuticals.
Over a 20-year period prior to founding Azur Pharma, Seamus was closely involved with Élan Corporation s growth and evolution from a drug delivery company into a research-focused pharmaceutical organization.
Seamus holds a Bachelor of Science in Pharmaceuticals and a Master of Science from Trinity College, Dublin, Ireland.
Chief Operating Officer
Eunan Maguire. co-founder of Adapt Pharma, serves as Chief Operating Officer and a member of the Board of Directors. Eunan was co-founder of Azur Pharma and served as President of its US business.
When Azur Pharma merged with Jazz Pharmaceuticals plc in 2012, Eunan continued as Senior Vice President of Strategy and Corporate Development and a member of the Executive Committee until 2013.
Prior to his work at Azur Pharma, Eunan was Vice President of Business Development at King Pharmaceuticals (acquired by Pfizer). From 1997 to 2004, he served as Vice President of Strategic Planning at Élan Corporation plc.
Eunan is a chartered accountant and holds an International Commerce degree from University College Dublin, Ireland. He is currently a Director with Profector Life Sciences, a business focused on transforming cell transfection.
Chief Financial Officer
David Brabazon. co-founder of Adapt Pharma, serves as Chief Financial Officer and a member of the Board of Directors. David was co-founder of Azur Pharma and served as its Chief Financial Officer. When Azur Pharma merged with Jazz Pharmaceuticals plc in 2012, David continued as Senior Vice President of Finance and Secretary until late 2012.
Prior to his work at Azur, David served as President of Finance and Group Financial Controller of Élan Corporation, with responsibility for financial control, taxation, and treasury.
David is a chartered accountant and holds a Master of Accounting from the University College Dublin, Ireland, and a Master of Business Administration from INSEAD, France. He serves as a Director of Headway Ireland Limited located in Ireland, which provides support and services to people with brain injuries.
Head of Technical Operations
Fintan Keegan serves as Head of Technical Operations for Adapt Pharma. Fintan was part of the founding management team at Azur Pharma, where he also led technical operations. When Azur Pharma merged with Jazz Pharmaceuticals plc in 2012, Fintan continued as Executive Vice President of Technical Operations and a member of the Executive Committee until 2014. Fintan also served as Chief Executive Officer of Gentium SpA, a subsidiary of Jazz Pharmaceuticals plc, during that time.
Before he served with Azur, Fintan served as Vice President of Quality at Élan Corporation plc, and he earlier served at Wyeth Medica Ireland Ltd. Fintan has more than 27 years of experience in manufacturing and related technical operations, including with the pharmaceutical industry. He worked with Merck Sharp and Dohme, National Medical Care, and the Institute of Clinical Pharmacology.
Fintan holds a Bachelor of Applied Science from Trinity College, Dublin, Ireland, and a Master of Science in Chemistry from the University of Bristol, United Kingdom.
President US Operations
Mike Kelly serves as President of US Operations for Adapt Pharma. Before joining Adapt, he was Chief Executive Officer and Board Member for Covis Pharmaceuticals, Inc. Prior to Covis, Mike was part of the founding management team at Azur Pharma as General Manager, U.S. Operations. When Azur Pharma and Jazz Pharmaceuticals plc merged in 2012, Mike continued as Senior Vice President of Sales and Marketing for Jazz through 2013.
Mike has more than 25 years experience in the pharmaceutical industry. Prior to his tenure at Azur, Mike served as Vice President of Commercial Operations at Guilford Pharmaceuticals, Vice President of Sales and Marketing at ViroPharma Incorporated, and held various commercial and medical roles at TAP Pharmaceuticals.
Mike holds a Bachelor of Science in Business Administration from The College of New Jersey and a Master of Business Administration from Rider University.
Chief Commercial Officer US
Matt Ruth serves as the US Chief Commercial Officer of Adapt Pharma. Before joining Adapt, he was the Vice President of CNS Commercial for Azur Pharma. When Azur Pharma merged with Jazz Pharmaceuticals plc in 2012, Matt continued as US Business Unit Lead for the Psychiatry Franchise.
From 2006-2007, he was Vice President of Sales and Managed Care at Avanir Pharmaceuticals before its acquisition by Azur, and from 2001-2006, he held various leadership positions with Allergan.
Matt holds a Bachelor of Science in Communications from Missouri State University and completed the General Management Executive Program at University of California, Los Angeles, in 2007.
July 12, 2016
Adapt Pharma to Launch Program to Raise Awareness, Expand Access and Facilitate Product Experience of NARCAN (Naloxone HCl) Nasal Spray – a new Treatment for Opioid Overdose.
July 6, 2016
Earlier today, Health Canada announced it will establish temporary access to the only U.S. Food and Drug Administration (FDA) approved, intranasal version of naloxone, NARCAN Nasal Spray, the medicat.
May 2, 2016
Adapt Pharma submits NDS to Health Canada for Naloxone Nasal Spray.